[New bone density conservation agents for osteoporosis under research and development: Zoledronate].
Wada
Seiki
S
Department of Clinical Science, Faculty of Pharmaceutical Sciences, Josai International University.
Fukawa
Takeshi
T
Kamiya
Sadahiro
S
D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001842:Bone and Bones / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D012106:Research; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid